STAT+: GSK touts lung cancer data from two drugs

GSK has announced positive results from the ARROS-1 trial of its drug Jideytro, also known as zidesamtinib, in patients with ROS1-positive non-small cell lung cancer who had not previously received treatment with a tyrosine kinase inhibitor. According to Investing.com, the trial showed that in 94 treatment-naïve patients, zidesamtinib achieved a 94% objective response rate after a median follow-up of 15.2 months, including a 15% complete response rate.

The trial also found that progression-free survival was 90% at 12 months, and median duration of response and median progression-free survival had not been reached at the time of analysis. Among 10 patients with measurable brain metastases at baseline, all responded to treatment, with 70% achieving complete clearance of detectable brain tumors.

GSK plans to submit a supplemental New Drug Application to the U.S. FDA this year to expand Jideytro's indication to include first-line treatment. The most common treatment-related adverse events were peripheral edema, weight increase, blood creatine phosphokinase increase, dysgeusia, and aspartate aminotransferase increase.

Brief written by urgent.news from STAT News, Investing.com — 2 reports on this story. Machine-written — may contain errors; check the original before relying on it.